Andrew Shales is an experienced leader with a strong commercial background in the pharmaceutical, clinical laboratory, and diagnostics businesses. He has specific expertise in strategic planning, commercial build-outs, and launch execution, especially with new companies and growth companies. Mr. Shales has led three startup pharma companies from inception to profitability by their third full year of operations. He has demonstrated success developing and leading high-performance commercial teams and managing successful domestic and international partnerships. He is known for leading teams that share a continuous focus on the critical activities and operating efficiencies that achieve committed goals and establish category and company franchises. Mr. Shales led pre-launch and launch marketing planning and execution for the anticonvulsant KEPPRA® (levetiracetam). KEPPRA is often cited as the product that established UCB Pharma in the U.S. pharmaceutical market. He also has been responsible for launching or relaunching more than twenty ethical pharma products including mega-brands and many niche brands. Mr. Shales holds a bachelor’s degree from King’s College in Wilkes-Barre, PA and is currently enrolled part-time in the MSJ program in Pharmaceutical and Medical Device Law and Compliance at Seton Hall Law School.
Ecoza now back in stock and available with longer 4-year dating
Resilia Pharmaceuticals Brings Neosalus® Cream and Neosalus® Lotion Back to Market
Resilia Pharmaceuticals Announces Relaunch of Solace® Eczema Cream on Amazon®
For help finding Resilia products click here